Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
Holding RPRX?
Track your performance easily
RPRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.20 - $31.66
Previous Close$27.54
Volume4.60M
Average Volume (3M)2.25M
Market Cap
$16.14B
Enterprise Value$25.22B
Total Cash (Recent Filing)$1.80B
Total Debt (Recent Filing)$7.60B
Price to Earnings (P/E)18.1
Beta0.67
Next Earnings
Feb 12, 2025EPS Estimate
$1.07Next Dividend Ex-Date
Nov 15, 2024Dividend Yield3.05%
Share Statistics
EPS (TTM)1.50
Shares Outstanding593,459,148
10 Day Avg. Volume1,813,753
30 Day Avg. Volume2,248,180
Standard Deviation0.06
R-Squared0.13
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.52
Price to Sales (P/S)7.21
Price to Cash Flow (P/CF)6.10
P/FCF Ratio6.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.27
Enterprise Value/Gross Profit10.71
Enterprise Value/Ebitda24.06
Forecast
1Y Price Target
$44.40Price Target Upside66.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Royalty Pharma News
PremiumStock Analysis & Ideas
Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ StocksBulls Say, Bears Say
Bulls Say
Financial PerformanceRoyalty Pharma reported another solid quarter and raised guidance.
Pipeline And DevelopmentRoyalty Pharma has several big pipeline assets in late-stage development that could launch in the next few years.
Strategic DealsDeploying ~$2bn on deals across 6 therapies during the quarter, and also stepping up the level of share repurchases.
Bears Say
Commercial RiskThere could be risk in the commercial ramp given Servier’s limited oncology sales experience in glioma and ex-US headquarters.
Management OwnershipThe bigger concern is the 80% shares owned by management post the 2025 lock-up period.
Stock PerformanceRPRX shares have underperformed the biotech index benchmark YTD.
---
Ownership Overview
8.80% Insiders
19.47% Mutual Funds
9.47% Other Institutional Investors
47.31% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $25.20 and its highest was $31.66 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Currently, no data Available
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Feb 12, 2025 which is in 94 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on Nov 06, 2024. The company reported $0.917 earnings per share for the quarter, missing the consensus estimate of $0.927 by -$0.01.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.21 which represents an annual dividend yield of 3.05%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is $1.07.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 448,131,560 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $0.917 in its last earnings report, missing expectations of $0.927. Following the earnings report the stock price went down -3.268%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Among the largest hedge funds holding Royalty Pharma PLC’s share is Viking Global Investors LP. It holds Royalty Pharma PLC’s shares valued at 316M.
---
Royalty Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.40 (66.67% Upside)
$44.40 (66.67% Upside)
Blogger Sentiment
Bullish
RPRX Sentiment 85%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 29.6%
Last 30 Days ▲ 32.9%
Last 30 Days ▲ 32.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.20%
12-Months-Change
Fundamentals
Return on Equity
17.62%
Trailing 12-Months
Asset Growth
13.79%
Trailing 12-Months
Company Description
Royalty Pharma PLC
New York-based Royalty Pharma Plc is a biopharmaceutical company, which is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.
---
RPRX Company Deck
---
RPRX Earnings Call
Q2 2024
0:00 / 0:00
---
RPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
---
RPRX Stock 12 Month Forecast
Average Price Target
$44.40
▲(66.67% Upside)
Technical Analysis
Best Analysts Covering RPRX
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-8.53%
reiterated a buy rating 2 months ago
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -8.53% per trade.
---